Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin

Biomedical Research (Japan)

Volumn 34, Issue 3, 2013, Pages 143-151

  Ogane, Naoki ^a   Yasuda, Masanori ^b   Kameda, Yoichi ^a   Yokose, Tomoyuki ^a   Kato, Hisamori ^a   Itoh, Ayumi ^c   Nishino, Satoshi ^c   Hashimoto, Yumi ^c   Kamoshida, Shingo ^c  

^a KANAGAWA CANCER CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARRIER PROTEIN; COPPER TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B3; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA; CATION TRANSPORT PROTEINS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PACLITAXEL; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879144621     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.34.143     Document Type: Article

References (25)

1. Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A and Guillemette C (2011) Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab 96, E330-339.
2. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15, 10-17.
3. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS and Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75, 228-234.
4. Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz AP, Ngan HY, Sideri M and Pecorelli S (2001) Carcinoma of the corpus uteri. J Epidemiol Biostat 6, 47-86.
5. Dobson PD and Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7, 205-220.
6. Hagenbuch BGC (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38, 778-801.
7. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R and Howell SB (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66, 817-823.
8. Holzer AK, Manorek GH and Howell SB (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70, 1390-1394.
9. Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P and Howell SB (2006) Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 54, 1041-1049.
10. Howell SB, Safaei R, Larson CA and Sailor MJ (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77, 887-894.
11. Larson CA, Blair BG, Safaei R and Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75, 324-330.
12. Lee Y-Y, Choi CH, Do I-G, Song SY, Lee W, Park HS, Song TJ, Kim MK, Kim T-J, Lee J-W, Bae D-S and Kim B-G (2011) Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum- based chemotherapy. Gynecol Oncol 122, 361-365.
13. Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T and Tamai I (2010) Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 122, 180-185.
14. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, Jobo T, Hatae M, Hiura M and Yaegashi N (2011) Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Ann Oncol 22, 636-642.
15. Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105, 103-104.
16. Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G and Economopoulos T (2008) Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 109, 250-254.
17. Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35, 649-662.
18. Pressler H, Sissung TM, Venzon D, Price DK and Figg WD (2011) Expression of OATP family members in hormonerelated cancers: potential markers of progression. PLoS ONE 6, e20372.
19. Siegel R, Ward E, Brawley O and Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212-236.
20. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER and Figg WD (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44, 152-167.
21. Smith NF, Acharya MR, Desai N, Figg WD and Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4, 815-818.
22. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ and Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3, 1543-1549.
23. Sovak MA, DuPont J, Hensley ML, Ishill N, Gerst S, Abu-Rustum N, Anderson S, Barakat R, Konner J, Poyner E, Sabbatini P, Spriggs DR and Aghajanian C (2007) Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 17, 197-203.
24. Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, Thalhammer T and Jäger W (2011) Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 65, 417-426.
25. Vandenput I, Vergote I, Leunen K, Berteloot P, Neven P and Amant F (2009) Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer 19, 1147-1151.